Show simple item record

dc.contributor.authorBuzdar, Amanen
dc.contributor.authorHowell, Anthonyen
dc.date.accessioned2009-10-01T12:04:02Z
dc.date.available2009-10-01T12:04:02Z
dc.date.issued2001-09
dc.identifier.citationAdvances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. 2001, 7 (9):2620-35 Clin. Cancer Res.en
dc.identifier.issn1078-0432
dc.identifier.pmid11555572
dc.identifier.urihttp://hdl.handle.net/10541/83173
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAndrostadienes
dc.subject.meshAndrostenedione
dc.subject.meshAromatase Inhibitors
dc.subject.meshBreast Neoplasms
dc.subject.meshEnzyme Inhibitors
dc.subject.meshFadrozole
dc.subject.meshFemale
dc.subject.meshHeadache
dc.subject.meshHumans
dc.subject.meshNausea
dc.subject.meshNitriles
dc.subject.meshTreatment Outcome
dc.subject.meshTriazoles
dc.subject.meshVomiting
dc.titleAdvances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Breast Medical Oncology, M. D., Anderson Cancer Center, University of Texas, Houston, 77030, USA.en
dc.identifier.journalClinical Cancer Researchen


This item appears in the following Collection(s)

Show simple item record